Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial February 27, 2018
Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial May 30, 2017
Intensity Therapeutics reports that INT230-6 Induces Protective T-Cell Immunity in preclinical models April 4, 2017
Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6 June 28, 2016
Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents June 2, 2016
Intensity Therapeutics reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation April 19, 2016
Intensity Therapeutics Preclinical Results Show AntiCancer Synergy of INT230-6 with Anti-PD-1 Compounds November 5, 2015
Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists October 22, 2015
Intensity Therapeutics, Inc. CEO to Speak at the 10th Annual Value-Based Oncology Management Forum October 12, 2015
Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting April 16, 2015
Intensity Therapeutics, Inc. to Present at the Biotech Showcase Conference in San Francisco January 6, 2015
Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference October 9, 2014
Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer September 2, 2014
Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute May 28, 2014
